.png){kind=icon}
.png){kind=icon}
Return
Protein S and Non–HDL-C Levels in LV Patients Treated With Rivaroxaban: A Monocentric Analysis
.png){kind=icon}
OA
AI
Y
Y
H
DOI：10.1155/dth/8761248.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Livedoid vasculopathy (LV) is a chronic, recurrent, occlusive vascular dermatosis with thrombotic and inflammatory components. The oral anticoagulant rivaroxaban has demonstrated efficacy and safety in the treatment of LV. This study investigated potential predictors of treatment response to rivaroxaban in patients with LV.
Keywords:
livedoid vasculopathy
predictive biomarker
rivaroxaban
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.4
Papers:
4.8K
Citations:
7.1K
Organization
Cited Papers